http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2593231-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc4f6a2a259d3aa3effccf74a56dc109 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
| filingDate | 2011-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0fae9697496592b805ea32903e05fc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcaf24baea8675b366bf7dc4e3e5c8b3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dcf5c00b9ae493d241e0e8c7695a42c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ecffe6b919266ebd18c627727ff7254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d858725d7b15674d8f0b7b05411e1e9 |
| publicationDate | 2016-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2593231-C2 |
| titleOfInvention | Methods for treatment using selective bcl-2 inhibitors |
| abstract | FIELD: medicine; pharmaceuticals. n SUBSTANCE: group of inventions concerns using 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulphonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide, or 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulphonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide, or their pharmaceutically acceptable salts for preparing drug. This device can be used for treating autoimmune diseases-systemic lupus erythematosus, lupous nephritis or Sjogren's syndrome in patient administered with therapeutically effective amount of this agent, for example, in range from 0.001 mg/kg to 1,000 mg/kg. Drug can be used in combination with binding protein for additional increase of efficiency of compound in desired place action. n EFFECT: inventions provide most selective inhibition of activity antiapoptotic Bcl-2 proteins with most low affinity than inhibition of activity of other proteins of family Bcl-2, including Bcl-x L , that require smaller doses of used compounds. n 12 cl, 9 ex, 12 dwg, 4 tbl |
| priorityDate | 2010-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 898.